Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis
ConclusionsThe efficacy and safety of golimumab in daily clinical practice were confirmed for the short- and long-term treatment of patients with active ulcerative colitis. Patients na ïve to the anti-TNF-alpha monoclonal antibody and those with a higher total Mayo score were more likely to respond to golimumab.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Gastroenterology | Inflammatory Bowel Disease | Italy Health | Laboratory Medicine | Ulcerative Colitis